Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ambion launches SARS (severe acute respiratory syndrome) virus RNA control:

This article was originally published in Clinica

Executive Summary

Ambion RNA Diagnostics (Austin, Texas) has launched a stable RNA control for use in the molecular detection of the coronavirus associated with Severe Acute Respiratory Syndrome (SARS). The company used its Armored RNA technology to create a viral RNA control that is packaged in protective, stabilising bacteriophage coat proteins. The control can endure long-term storage in plasma or serum, and is non-infectious.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT062728

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel